ArticleMicrobes and infection
The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement.
Article in Microbes and infection. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.
- Meta-analysis of host transcriptional responses to SARS-CoV-2 infection reveals their manifestation in human tumors.Scientific reports · 2021Pooled it
- Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine.Frontiers in immunology · 2026Article
- The severity of COVID-19 infection correlation with IL-17 polymorphism.Archives of Razi Institute · 2025Article
- Pulmonary Myeloid Cells in Mild Cases of COVID-19 Upregulate the Intracellular Fc ReceptorInternational journal of molecular sciences · 2025Article
- Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.Clinical and translational allergy · 2025Review
- Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2.Frontiers in immunology · 2025Article
- Genetic, Clinical, Epidemiological, and Immunological Profiling of IgG Response Duration after SARS-CoV-2 Infection.International journal of molecular sciences · 2024Article
- Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS).Respiratory research · 2024Review
- Accelarated immune ageing is associated with COVID-19 disease severity.Immunity & ageing : I & A · 2024Article
- Responses of Helper T Cell Subsets at Diagnosis and After Discharge in Patients with Non-Severe COVID-19: A Prospective Observational Study.Journal of clinical practice and research · 2024Article
- Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Role of Serum Ferritin, D-Dimer, and C-Reactive Protein Parameters in COVID 19 Severity.Archives of Razi Institute · 2023Article
- Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance.Journal of inflammation (London, England) · 2023Review
- COVID-19: A Comprehensive Review on Cardiovascular Alterations, Immunity, and Therapeutics in Older Adults.Journal of clinical medicine · 2023Review
- Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19.Frontiers in immunology · 2023Article
- Innate and adaptive immunity to SARS-CoV-2 and predisposing factors.Frontiers in immunology · 2023Review
- Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series.Journal of clinical medicine · 2022Article
- Article
- Novel coronavirus mutations: Vaccine development and challenges.Microbial pathogenesis · 2022Review
- Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities.Clinical immunology (Orlando, Fla.) · 2022Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence points to host Th17 inflammatory responses as contributing to the severe lung pathology and mortality of lower respiratory tract infections from coronaviruses. This includes host inflammatory and cytokine responses to COVID-19 caused by the SARS-2 coronavirus (SARS CoV2). From studies conducted in laboratory animals, there are additional concerns about immune enhancement and the role of potential host immunopathology resulting from experimental human COVID-19 vaccines. Here we summarize evidence suggesting there may be partial overlap between the underlying immunopathologic processes linked to both coronavirus infection and vaccination, and a role for Th17 in immune enhancement and eosinophilic pulmonary immunopathology. Such findings help explain the link between viral-vectored coronavirus vaccines and immune enhancement and its reduction through alum adjuvants. Additional research may also clarify links between COVID-19 pulmonary immunopathology and heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.